Gancao Xiexin decoction combined with mesalazine in the treatment of ulcerative colitis: A protocol for a systematic review and meta-analysis

Medicine (Baltimore). 2020 Nov 20;99(47):e23038. doi: 10.1097/MD.0000000000023038.

Abstract

Backgroud: Ulcerative colitis (UC) is a chronic inflammatory disease that involves the rectum, colon and ileum. Gancao Xiexin decoction (GCXXD) is a classic herbal formula in Shanghanlun. More and more research evidence shows that GCXXD has a certain therapeutic effect on UC. Therefore, we designed this study protocol aim to evaluate the efficacy and safety of GCXXD combine with mesalazine for UC.

Methods: We will systematically search 6 databases, including PubMed, the Cochrane Library, EMBASE, CNKI, VIP, Wang-fang database up to July 2020 to obtain eligible studies. The primary outcomes will focus on the clinical effectiveness. Review Manager 5.3 software will be used for data analysis.

Results: This study will provide the systematic evidence of UC treated with GCXXD combine with mesalazine.

Conclusion: The findings of this meta-analysis will provide evidence to judge whether GCXXD combine with mesalazine is a more effective intervention compare to mesalazine only for patient of UC.

Inplasy registration number: INPLASY202080008.

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Colitis, Ulcerative / drug therapy*
  • Drug Therapy, Combination
  • Drugs, Chinese Herbal / therapeutic use*
  • Humans
  • Mesalamine / therapeutic use*
  • Meta-Analysis as Topic
  • Research Design*
  • Systematic Reviews as Topic

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Drugs, Chinese Herbal
  • Xiexin decoction
  • Mesalamine